The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Amicus™ high collection efficiency yields multiple products per donor for the lowest-cost platelet production. It is designed to adapt to the requirements of different collection settings. Let ...

A leading source of practice, career, and business development analysis and insights for litigators. The Litigation Section provides litigators of all practice areas the resources needed to be ...

It's time to renew your membership and keep access to free CLE, valuable publications and more. Your membership has expired - last chance for uninterrupted access to free CLE and other benefits.